13 results about "Combined Vaccines" patented technology

The invention discloses a modular combined vaccine soluble microneedle patch based on a mechanical interlocking tenon-and-mortise structure as well as a preparation method and application of the modular combined vaccine soluble microneedle patch. According to the combined and spliced micro-needle vaccine patch designed by the invention, synchronous delivery of various vaccines is realized by virtue of a micro-needle technology through fragmented loading and mechanical interlocking'mortise and tenon 'structural design, mutual interference among different vaccines is reduced at the same time, efficient protection can be provided for groups needing multi-vaccine protection by virtue of one-time inoculation, the number of inoculants is reduced, and the immune procedure is simplified; vaccine hesitation is reduced, and inoculation rate is increased; meanwhile, the biosoluble material of the microneedle structure can quickly release antigens in the skin to stimulate immune cells to aggregate so as to enhance the immune effect; the micron-sized needle array (lt; 500 m) acts on the superficial layer of the skin, is painless and can be designed into a self-adhesive patch, so that the inoculation compliance is improved; single-dose inoculation can also reduce medical cost, is suitable for resource-deficient regions, improves accessibility and burdenability, and accelerates establishment of a population immune barrier.

The application discloses a competitive ELISA detection method for Hib polysaccharide in an aluminum-containing adjuvant vaccine, and specifically, the method comprises the following steps: enzyme label plate preparation: coating Hib stock solution or PRP derivative on an enzyme label plate to prepare an enzyme label plate required for ELISA reaction; aluminum adsorption Hib sample treatment: blocking aluminum adjuvant adsorbed Hib reference and aluminum adjuvant containing vaccine samples with BSA, respectively, and then diluting the aluminum adjuvant adsorbed Hib reference and aluminum adjuvant combined vaccine samples after blocking; ELISA detection: adding the diluted aluminum adjuvant adsorbed Hib reference and aluminum adjuvant containing vaccine samples into the enzyme label plate, respectively, and then adding Hib specific antibody, generating ELISA signals through enzyme label antibody catalysis of substrates, establishing a mathematical relationship between absorbance and Hib polysaccharide content, and quantitatively calculating the Hib polysaccharide content in the aluminum adjuvant containing vaccine sample.

Disclosed in the present invention is a compound adjuvant combined vaccine, comprising an immunogenic composition and a compound adjuvant. The immunogenic composition comprises a pertussis antigen, a diphtheria antigen and a tetanus antigen; and the compound adjuvant is composed of an aluminum adjuvant and a TLR9 receptor agonist. Further disclosed in the present invention is a use of the compound adjuvant in the preparation of the compound adjuvant combined vaccine for preventing pertussis, diphtheria and tetanus in a subject.

The present disclosure provides vaccine compositions comprising a plurality of different antigens. Also provided are nucleic acid vaccine compositions comprising one or more nucleic acids encoding a plurality of different antigens. The plurality of different antigens include a combination of influenza antigens. The vaccine compositions may be formulated as mRNA / LNP, recombinant proteins, virus-like particles (VLPs), or DNA for delivery. Methods of preventing influenza infection and methods of inducing an immune response are also disclosed.

The invention provides a combined vaccine based on Th1 / Th2 immune dynamic equilibrium as well as a preparation method and application of the combined vaccine. Subcutaneous delivery of interleukin 12 (IL12) and antigen (such as ovalbumin OVA) mRNA is adopted in the early stage of tumor occurrence, so that specific antigen recognition and T cell immune response of an organism are activated; when immune response enters a function decline stage, the tumor microenvironment is regulated through intratumor delivery of interleukin 4 (IL4) mRNA, the metabolic activity of T cells is maintained, and the depletion of the T cells is delayed. Through space (subcutaneous / intra-tumor) and time (early stage / middle stage) separated delivery of different immune factors, 'start-steady state maintenance 'type immune stylization regulation and control are realized, antigen-specific CTL reaction and persistent anti-tumor effect are remarkably enhanced, and the problem of immune bias caused by independent use of the antigen-specific CTL reaction and the persistent anti-tumor effect is solved.

The invention belongs to the technical field of poultry vaccines, and particularly relates to a chicken new tributary method adeno-quintuplet vaccine and a preparation method thereof.The chicken new tributary method adeno-quintuplet vaccine comprises chicken Newcastle disease venom, infectious bronchitis venom, avian influenza venom, infectious bursal disease virus liquid and fowl adenovirus venom, and the preparation method of the Newcastle disease venom comprises the steps that firstly, frozen MDCK suspension cells are provided; the frozen MDCK suspension cells are recovered at the temperature of 40-45 DEG C; 2, transferring the resuscitated MDCK suspension cells to a serum-free culture medium; according to the invention, the inactivated vaccine is prepared from the Newcastle disease venom, the infectious bronchitis venom, the avian influenza venom, the infectious bursal disease virus liquid and the fowl adenovirus venom by adopting a superstrong concentration process and a high-quality adjuvant, so that after animals are immunized, antibodies are generated quickly, the titer is high, the protection period is long, and the occurrence and spreading of epidemic diseases are prevented; and people can conveniently put multi-combined vaccines to cope with continuously changing epidemic disease prevention and control situations.

The invention provides a composite vaccine adjuvant based on ergothioneine-sulfhydrylated polypeptide and a vaccine composition and application thereof, and belongs to the crossing field of biotechnology and medicine (including veterinary use). The composite vaccine adjuvant comprises a component A and a component B, wherein the component A comprises the following components in percentage by weight: 0.5%-5.0% of L-ergothioneine, 0.3%-2.0% of (Gly-SH) n oligopeptide, 2.0%-8.0% of aluminum hydroxide and / or aluminum phosphate, 1.0%-3.0% of a targeting carrier, 5.5%-13.0% of a freeze-drying protective additive and the balance of a buffer solution; the component B is CpG ODN, and the final concentration of the component B is 10-25 mu g / mL. The composite vaccine adjuvant system integrates sulfhydrylation modification enhanced combination and multi-component synergistic immunization, can be used for inducing balanced Th1 / Th2 immune response of mammals (including human, pigs, cattle and the like) and birds (chicken, ducks and the like) to intracellular / extracellular pathogens, and can be adapted to subunit vaccines, inactivated vaccines, recombinant antigen vaccines and combined vaccines; meanwhile, healthy groups and immunosuppressive groups (young, stress substance and immunodeficient groups) are compatible.

The invention pertains to a combination of a first vaccine comprising anon-replicating immunogen of porcine circovirus type 2 (PCV-2) and a non-replicating immunogen of Mycoplasma hyopneumoniae, and a second vaccine comprising a live attenuated porcine reproductive and respiratory syndrome (PRRS) virus, for use in prophylactically treating a pig against an infection with PCV-2, an infection with Mycoplasma hyopneumoniae and an infection with PRRS virus, by associated separate injection of the first vaccine and the second vaccine into a tissue of the pig at a first and a second injection site respectively, wherein the first and second injection sites are at most 5 cm apart from each other.

The application discloses a combined vaccine for preventing hand-foot-mouth disease, which comprises inactivated enterovirus 71 virus, and inactivated coxsackievirus A 16 virus, coxsackievirus A 10 virus and coxsackievirus A 6 virus. The application also discloses a method for preparing the combined vaccine, and the prepared vaccine has good adsorption effect and stability. The multiple antigens do not interfere with antigenicity and immunization effect of each other after immunizing an object, and have good immunogenicity and safety. The use of the combined vaccine can obviously simplify a vaccine inoculation procedure, improve inoculation efficiency and reduce cost.

Disclosed herein are immunogenic compositions comprising ribonucleic acids (RNA) and combination vaccines that include saponin-based adjuvants, as well as methods of using the immunogenic compositions. Methods for preparing the immunogenic compositions, and methods of administering the immunogenic compositions are also disclosed.

The invention relates to a HPV vaccine composition and a dengue vaccine composition for use in a method of preventing an HPV-associated disease and dengue disease in a subject or in a subject population, the method comprising concomitantly administering the HPV vaccine composition and the dengue vaccine composition, wherein the dengue vaccine composition is a tetravalent dengue composition comprising live, attenuated DENV-1, DENV-2, DENV-3 and DENV-4 strains and wherein the method provides combined vaccine efficacy against all four serotypes of the dengue virus and non-inferiority of the immune respone to the HPV vaccine composition compared to a mono-administratrion of the HPV vaccine composition.

The application provides a monoclonal antibody 4E3 and a monoclonal antibody 4D5 which specifically bind to a SEA type O foot-and-mouth disease virus, and a double-antibody sandwich kit with the monoclonal antibody 4E3 as a coating antibody and the monoclonal antibody 4D5 as an enzyme-labeled antibody; the kit can quantitatively detect the content of the SEA type O foot-and-mouth disease virus-like particles, and can detect the content of the SEA type O foot-and-mouth disease virus-like particles in a single vaccine, a multivalent vaccine or a combined vaccine; and can quantitatively detect the content of antigens in a semi-finished vaccine or a finished vaccine.